Crain’s Cleveland Business (subscription required): Nathan Berger, the Hanna-Payne Professor of Experimental Medicine, and Rong Xu, professor at the School of Medicine, discussed their new research finding that a class of medications used to treat Type 2 diabetes and weight loss—under which the newly popular Ozempic and Wegovy are categorized—could reduce the risk of colorectal cancer.
